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Abstract
BACKGROUND: Nanoparticles represent promising drug carrier 
systems. In the case of cytostatics such as doxorubicin, carrier 
colloid systems as human serum albumin (HSA) nanoparticles, 
may increase their therapeutic efficiency and decrease their 
side-effects (toxicity) and any potential multidrug resistance. In 
the present study, doxorubicin, as a widely used antineoplastic 
agent, was incorporated into the matrix of human serum albu-
min and three different particle-sized doxorubicin-loaded HSA 
nanoparticles were prepared, using a previously described 
desolvation method. Our objective was to find out if different 
particle sizes of colloid carriers can allow regarding the given 
cytostatic agent.
MATERIAL AND METHODS: The three prepared nanoparticles 
were labelled using technetium (Tc-99m) and were tested for 
their physicochemical colloidal quality, fluctuations, and radio-
chemical stability. Biodistribution of different-sized radiolabelled 
colloids were determined by means of scintigraphic imaging stu-
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dies in healthy male Wistar rats. Images were taken by gamma 
camera at several times and organ uptakes were estimated by 
quantitative ROI analysis.
RESULTS: In vitro measurements showed that more than 95% 
of doxorubicin proportion was permanently adsorbed to human 
serum albumin. Radiolabelled doxorubicin-loaded particles had 
high-degree and durable labelling efficiency and particle size 
stability. Biodistribution results had a close correlation to earlier 
described results of radiocolloids in similar particle size ranges. 
In vivo examinations verified that colloid carriers have insignifi-
cant size fluctuations after an intravenous application and they 
show the proper distribution according to their particle size.
CONCLUSIONS: Our investigations verified that different and 
stable particle sizes make drug carrier HSA nanoparticles pos-
sible to apply different drug targeting in a potential clinical use. 
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Introduction
In recent years new methods have been developed with na-
noparticles as drug delivery systems (nanocarriers) in oncological 
applications to targeted delivery antineoplastic drugs. The use 
of colloidal carriers can decrease side-effects in treatment and 
increase therapeutic efficiency [1]. In cancer therapy doxorubicin 
is a frequently used antineoplastic agent, but in clinical applica-
tions this anti-cancer drug is limited due to its high cardiotoxicity 
[2, 3]. A promising solution to decrease cardiotoxicity could be 
binding doxorubicin to a drug delivery nanoparticle system [4]. 
Nanoparticles show a high drug loading efficiency with minor 
drug leakage, high storage stability, and may overcome cancer 
cell multidrug resistance [5, 6]. Earlier, doxorubicin was bound to 
colloidal carriers made from several agents such as poly(butyl 
cyanoacrylate) (PBCA) [7, 8], poly(isohexyl cyanoacrylate) (PIHCA) 
[9], poly(lactic-co-glycolic acid) (PLGA) [10], and gelatin [11, 12]. 
Doxorubicin-loaded colloids have benefits in comparison to 
the normal doxorubicin solutions: firstly, passive targeting due to 
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the enhanced permeation and retention effect (EPR effect, [13]) 
that results from the properly selected particle-size distribution, 
and secondly, elimination of the multidrug resistance in more 
cancer cell lines [14].
Several methods have been described for bounding drugs to 
nanoparticulate systems, such as surface attachment of drugs to 
nanoparticles or polymers [6, 15], adsorption to the preformed car-
rier system, and incorporation into the particle matrix during col-
loid preparation [4]. While simple adsorption to preformed carrier 
nanoparticles could lead to the early desorption of targeting ligand, 
incorporation protects drug-loaded particles from early drug loss, in-
activation, or degradation during storage and after administration [4].
In the present study, doxorubicin was incorporated into the 
matrix of human serum albumin, and three different particle-sized 
fractions of doxorubicin-loaded HSA nanoparticles were prepared 
using a previously described desolvation method [16, 17]. HSA 
nanoparticles offer several specific advantages [16]: these colloid 
compounds are biodegradable and well-tolerated, preparation 
is easy and reproducible [17], and it is possible to bind targeting 
ligands to particles by covalent bonding, due to the presence of 
functional groups [18–21].
The attained nanoparticles were labelled with technetium 
(Tc-99m) and investigated for their physicochemical (doxoru-
bicin-conjugating) radiochemical purity. Particle sizes and their 
stabilities and fluctuations were measured by dynamic light scat-
tering, and examinations were reinforced by TEM images.
Different biodistributions of different sized radiocolloids were 
investigated in healthy Wistar rats. A previously designed protocol 
was applied to find out correlations with earlier biodistribution 
studies of comparable particle-sized nanoparticles [22–26]. Our 
further aim was to verify the lack of any incidental, too high parti-
cle-size fluctuations and degradation after intravenous injection.
Material and methods
Chemicals
Human serum albumin was obtained from C.A.F.-D.C.F. 
cvba-scrl (albumin 20%), and glutaraldehyde 8% solution 
was obtained from Sigma (Steinheim, Germany). Doxorubicin 
(50 mg/25 ml doxorubicinum chloratum) and saline solution 
(“Salsol A”, 0.9% w/v of NaCl) were from TEVA (Salsol A, Teva Phar-
maceutical Works Ltd., Debrecen, Hungary). 99mTc-pertechnetate 
was derived from an UltraTechnekov (10.75 GBq) technetium 
generator (Covidien Imaging Solutions, USA). ACN (Acetonitrile) 
HPLC-grade was from Carlo Erba, and other solvents such 
as ethanol, MEK (Methil Ethil Ketone), and all other reagents were 
purchased from Reanal Ltd. (Budapest, HU) and were of analytical 
grade. ITLC-SG was obtained from Pall Corporation. Chemicals for 
animal experiments, such as xylazine hydrochloride and ketamine 
hydrochloride, were obtained from CP-Pharma, Germany.
Preparation and characterization 
of doxorubicin-loaded HSA nanoparticles
Preparation of different-sized, doxorubicin-loaded 
HSA nanoparticles
A total of 200 μl of doxorubicin solution (1 mg/ml diluted 
doxorubicinum chloratum sol.) was added to 200 μl (20 mg/ml) 
HSA solution. As previously described, the pH value of this ini-
tial HSA solution can influence the resulting particle sizes [17]. 
Therefore, three different pH settings (pH = 6.2, pH = 7.5, 
and pH = 8.2) were used by adding 0.1 N HCl or 0.1 N NaOH. 
The three mixtures were incubated under 650 rpm stirring for 
2 hours at room temperature to adsorb doxorubicin to human 
serum albumin [4, 27]. For the desolvation method 3 ml 96% 
v/v ethanol was added using a calibrated Masterflex tubing 
pump (Cole-Palmer Co., Chicago, Ill., USA) at 1 ml/min speed 
and continuous stirring (650 rpm). After the disolvation process, 
10 μl of 8% glutaraldehyde solution was added to induce particle 
crosslinking. This process was carried out under stirring (650 rpm) 
incubation for 24 hours at RT. Prepared nanoparticles were 
purified by centrifugation (16000 g, 8 min) and redispersion in 
phosphate buffer (pH = 7.5) by vortexer [27] and 5 minutes of 
ultrasonication [4].
Determination of non-adsorbed doxorubicin 
proportion  
After centrifugation (16,000 g, 8 min) and redispersion in 
phosphate-buffer, the collected supernatants were used to 
determine the non-adsorbed doxorubicin ratio. For the quanti-
fication of doxorubicin in the supernatant samples, an Agilent 
1200 HPLC system (Agilent Technologies Inc.) with UV-VIS de-
tector was applied. A LiChroCART® 250-4 LiChrospher® 100 
RP-18 reverse phase column (Merck, Germany) was used for the 
assay, and separation was achieved using an isocratic mixture 
of water and acetonitrile (7:3) containing 0.1% trifluoroacetic 
acid [28] at a flow rate of 0.8 ml/min. Doxorubicin was quanti-
fied by UV (250 nm), and the retention time was about 12 min 
[4]. Non-adsorbed doxorubicin quota was followed up 1 and 
24 hours and 7 days after preparation. Samples were stored 
at RT in a dark place.
Characterization of particle size and colloid stability
Particle size and polydispersity of attained colloids were 
measured by dynamic light scattering using a Dynapro 
instrument (Proteinsolutions Inc., VA, USA) as described 
earlier [23]. Samples were diluted 1:10 with saline and 
were measured at room temperature. Colloidal stability of 
nanoparticles was followed up 1, 2, 8, and 24 hours and 2, 
4, and 7 days after preparation. Samples were stored at RT 
in a dark place.
Transmission electron-microscopy examinations
Although particle fraction-ranges of the examined sam-
ples were near to the upper threshold of the measuring range for 
laser a scattering instrument (6 microns), TEM examinations were 
carried out to verify that the particles were in the earlier determined 
ranges.
Doxorubicin-loaded HSA nanoparticle solutions were pre-
pared according to the single-droplet negative staining technique 
[29] using carbon coated formvar copper grids and ammonium 
molybdate as a contrasting solution, and they were examined 
with a transmission electron-microscope (TEM) at various mag-
nifications (JEOL, Japan). Pictures were taken with a MegaView 
III camera and processed with the Soft Imaging Systems analy-
sis program.
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Labelling method and in vitro radiochemical stability
For labelling, 200 μg SnCl2 (x2H2O) was added to 2 ml of 
Doxo-HSA-Colloid as a reducing agent, then 1ml (1000 MBq acti-
vity) of generator-eluted 99mTcO4
- (aqueous pertechnetate solution) 
was added to the solvent. Labelling was performed in 60 min incuba-
tion at RT [28]. Radiochemical purity was examined by means of thin 
layer chromatography, using silica gel as the coating substance on 
a glass-fibre sheet (ITLC-SG) [30]. Plates were developed in methyl 
ethyl ketone. We applied a Raytest MiniGita device (Mini Gamma 
Isotope Thin Layer Analyzer) in Radiopharmacy Ltd. to determine 
the distribution of radioactivity in the developed ITLC-SG plates. We 
examined labelling efficiency 1, 6, and 24 h after labelling. Radio-
chemical samples were stored at RT in a dark place.
In vivo examinations, animal experiments
The aim of in vivo examinations was to observe particle-size 
changes or degradation after intravenous injection and to find 
out possible correlations with earlier presented biodistribution 
results of HSA colloids among the same size-ranges. These HSA 
products were earlier described in studies concerned with lym-
phoscintigraphy [23], lung scintigraphy [22], and other particle 
size-dependent biodistribution tests [25, 26].
The biological behaviour of different-sized colloids was as-
certained by carrying out scintigraphic imaging studies in healthy 
male Wistar rats weighing 180–200 grams. Then 0.2 ml (120 MBq 
of 99mTc) of the radiolabelled colloids was administered through 
the tail vein of the animals. Dorso-vent ral and left-lateral ima-
ges were taken with a single-head digital SPECT gamma camera 
(Nucline X-ring, Mediso) at 5, 15, 30, and 60 minutes and 2, 8, 
and 22 hours post-injection using a LEHR collimator to determine 
the in vivo localization of injected radioactivity. Prior to the imaging 
the animals were anaesthetized by administering a combination 
of xylazine hydrochloride and ketamine hydrochloride intraperito-
neal. The gamma camera was previously calibrated for the 140 
keV gamma photon of 99mTc. All the images were acquired with 
60 second time-prerequisites using a 1024 × 1024 × 16 matrix 
size. Critical organs, e.g. heart, liver, spleen, shoulder (representing 
the bone marrow uptake), and urinary bladder, were drawn around 
and organ uptakes were estimated by quantitative ROI analysis.
All the animal experiments reported here were carried out 
in strict compliance with the relevant national laws of Hungary. 
This study was approved by the Institutional Ethical Board.
Results
Non-conjugated doxorubicin concentration
Quantification of doxorubicin in the supernatant sam-
ples showed that at 1.0 mg/ml doxorubicin concentration more 
than 95% of the drug was adsorbed to nanoparticles. Doxorubicin 
loading efficiency was examined 6, 24, and 48 h after biological ap-
plication of labelled nanoparticles and each quantification showed 
that more than 95% of the doxorubicin remained bound to the HSA.
Particle size measurements and colloid stability
For the radiolabelling experiments three samples were manu-
factured with different mean diameters (about 180, 430, and 1800 
nm) and particle-size distributions at different initial pH settings in 
due course of preparation. Fractions of nanoparticles are illus-
trated in a common particle-size distribution histogram (Figure 1). 
Representative values of nanoparticle fractions are summarized 
in Table 1. Relatively high (35...45%) polydispersity values belong 
to mean diameters (MD) 180, 430, and 1800 nm.
Fluctuations of particle-sizes were followed up for 1 week 
and the average diameter, polydispersity, and fraction-range val-
ues were measured at different times. Results are summarized in 
Table 2 and illustrated in Figure 2. The diameter of the particles fluc-
tuated within a 2% range, but changes were not unidirectional or 
trend-like. The180 nm and 430 nm MD nanoparticles had 1.8% 
Figure 1. Particle-size distribution histogram of the three nanoparticle samples: maximum relative intensities were set to 1 to compare their size 
distribution in a common histogram.
Table 1. Representative values of nanoparticle-fractions measured immediately after preparation
No.             Sample Mean diameter Polydispersity Total fraction range
1. 99mTc-Doxo-HSA-Coll 180 176 nm 43.3% 65–405 nm
2. 99mTc-Doxo-HSA-Coll 430 429 nm 44.1% 165–1044 nm
3. 99mTc-Doxo-HSA-Coll 1800 1764 nm 35.5% 755–3762 nm
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and 1.2% average particle-size growth, while the 1800 nm MD 
nanoparticles had 1.9% average diameter decrease during the 
follow-up. Thus doxorubicin-loaded nanoparticles showed a high 
degree of particle-size stability.
At different times, mean particle-diameters showed fluc-
tuations with an ± SD = 3.5…4.7%, but average particle size 
changes were insignificant during the 1st week (Table 2). 
TEM images of colloids
The TEM examination revealed the presence of mostly 
spherical-shaped particles (Figure 3). Each sample showed broad 
size-distribution, but each observed size of particles was in the 
previously determined particle-fraction ranges. Besides, we could 
not see any particles larger than 6 microns in the largest product 
(99mTc-Doxo-HSA-Coll1800). It was important because the upper 
threshold of size-measuring in the applied laser scattering method 
was 6 microns. Thus, light scattering measurements were rein-
forced by TEM images.
Labelling efficiency, radiochemical purity, 
and stability
Efficiency of Tc-99m binding was examined 1, 6, and 24 h 
after labelling. Radiochemical samples were stored at RT in a dark 
place. Measurements verified that 1 hour after labelling each 
colloid had at least 95% radiochemical efficiency and 6 and 24 h 
after labelling the products kept radiochemical stability. Measured 
labelling efficiencies even increased to 98…99% (Figure 4).  
In vivo examinations
All the injected animals survived the experiments and no clinical 
side-effects (screaming, salivation, tremor, dyspnoe, diarrhoea, 
restlessness, or state of coma) were recorded in the rats. There 
was no sign of radioactivity in thyroid, salivary gland, or gastric 
mucosa at any time, indicating a high radioactive yield and stable 
in vivo labelling of all three agents.
The applied radiolabelled nanoparticles disappeared from 
the blood-stream relatively quickly. In the first 5 minutes post-ap-
Figure 2. In vitro colloid size-stability examination of the different-sized 
doxorubicin-loaded nanoparticles: fluctuations of average diameter 
values with polydispersities (illustrated as ± SD).
Table 2. Colloid stability in nanometre values: measured mean diameters (“Mean D”) immediately after preparation (“T0” time point) 
with polydispersity values (“Polyd”),  average, and ± SD values during the 7 days of follow-up
99mTc-Doxo-HSA-Coll180 99mTc-Doxo-HSA-Coll430 99mTc-Doxo-HSA-Coll1800
Mean D [nm] Polyd [nm] Mean D [nm] Polyd [nm] Mean D [nm] Polyd [nm]
T0 (starting) 175.8 76.1 429 189.3 1764 626.1
Average of 7 days 176 74.1 426.1 193.8 1817.7 623.8
±SD of 7 days 8.3 11.9 14.6 26.9 39.3 60.3
SD — standard deviation
Figure 3. Transmission electron-micrographs of doxorubicin-loaded HSA nanoparticles. A. 99mTc-Doxo-HSA-Coll180; B. 99mTc-Doxo-HSA-Coll1800.
A B
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plication, no large vessels were visualized. The two smaller parti-
cles were quickly taken up by the RES organs (liver, spleen, bone 
marrow) and the accumulated radioactivity immediately started to 
wash-out through the urinary tract (kidneys, urinary bladder, urine). 
However, almost 80% of the applied greatest radiolabelled agent 
localized in the lungs, even on the first scans (Figure 5). 
Only minor differences were recognized between the colloid 
particles No. 1 and 2 (average diameter 180 nm and 430 nm), 
respectively.  Both radiocolloids were excreted in the same amount 
(nearly 50% in 22 hours post application) through the urinary tract 
of the animals.
The greater doxorubicin-loaded colloid (99mTc-Doxo-HSA-Coll 
1800), however, markedly differed from the two smaller ones. The 
major proportion of radioactivity (78.6%) appeared in the lungs, 
much less but increasing and visible in the liver, and no appear-
ance was documented in the scans in the spleen and skeleton 
(Table 3, Figure 6).  The greater radiolabelled compounds located 
in the lungs disaggregated later, and the smaller particles re-
located mainly in the liver (Table 3A, 3B, Figure 7). This is the 
explanation of the observation that the measured radioactivity 
Figure 4. Radiochemical measurements of the 
99mTc-Doxo-HSA-Coll430 in ITLC-SG with Raytest MiniGita scanner, 
at different times: labelled nanocolloids are at starting point, free 
99mTc-pertechnetate runs with the front (Rf ≈ 1).
Chromatogram Substance R/F Area 
counts
Area 
(%)
1 h  Reg #1 0.000 21,930.09 97.37
Reg #2 0.948 592.09 2.63
6 h  Reg #1 0.004 15,509.48 99.98
Reg #2 0.939 592.09 0.02
24 
h
 Reg #1 0.009 17,140.33 99.88
Reg #2 0.924 20.67 0.12
Figure 5. Ventrodorsal whole body scans of Wistar rats after intravenous application of different sized doxorubicin-loaded HSA nanoparticles. 
Injected dose was 60 MBq/200 μl. 1: 99mTc-Doxo-HSA-Coll180, 2: 99mTc-Doxo-HSA-Coll430, 3: 99mTc-Doxo-HSA-Coll1800.
 1 2 3
 1 2 3
 1 2 3
 1 2 3
5 min
15 min
30 min
60 min
2 h
8 h
22 h
60
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Table 3. Biodistribution of radiocolloids: summary of calculated % ID values of the three radiocolloids taken from ROI data of scan images. 
Measured counts were adjusted to initial time with the respective decay of Tc-99m isotope
5 min 15 min 30 min 60 min 2 h 8 h 22 h
99mTc-Doxo-HSA-Coll180
Total 100.00% 95.70% 96.50% 93.80% 89.40% 74.30% 55.70%
Lungs 6.30% 6.20% 4.50% 4.30% 4.60% 2.50% 0.90%
Liver 72.50% 71.30% 68.40% 67.10% 63.80% 50.90% 37.10%
Spleen 2.20% 1.00% 2.40% 1.20% 2.80% 2.70% 1.40%
Kidneys 1.70% 1.90% 2.60% 1.70% 3.10% 5.60% 3.80%
Bladder 1.00% 1.20% 1.80% 0.70% 2.90% 1.90% 1.00%
Excreted radioactivity 4.30% 3.50% 6.20% 10.60% 25.70% 44.30%
99mTc-Doxo-HSA-Coll430
Total 100.00% 99.10% 98.90% 97.20% 88.00% 71.90% 51.30%
Lungs 5.00% 5.20% 5.40% 4.90% 4.00% 3.20% 1.60%
Liver 73.90% 72.80% 70.10% 64.90% 59.70% 45.70% 31.40%
Spleen 1.70% 1.90% 2.00% 3.30% 4.00% 3.50% 3.50%
Kidneys 2.20% 2.10% 1.90% 4.70% 3.30% 3.80% 3.00%
Bladder 0.60% 1.50% 2.00% 4.70% 4.50% 2.50% 1.10%
Excreted radioactivity 0.90% 1.10% 2.80% 12.00% 28.10% 48.70%
99mTc-Doxo-HSA-Coll1800
Total 100.00% 88.70% 89.60% 91.20% 91.40% 82.60% 71.80%
Lungs 78.60% 71.00% 68.90% 67.20% 61.20% 39.90% 12.00%
Liver 8.30% 9.40% 9.30% 11.20% 14.90% 22.50% 29.00%
Spleen 0.30% 0.60% 1.40% 1.70% 0.60% 1.70% 2.30%
Kidneys 0.70% 0.80% 1.00% 2.00% 1.20% 2.50% 2.00%
Bladder 0.10% 0.10% 0.20% 0.20% 0.10% 1.60% 0.80%
Excreted radioactivity 11.30% 10.40% 8.80% 8.60% 17.40% 28.20%
Figure 6. Injected dose percentage values in lungs after application.
in the lungs decreased approximately by the same amount as it 
increased at that time in the liver.  Only 28% of administered 
radioactivity excreted via the urinary tract in 22 hours post ap-
plication (Figure 8).
Biodistributions showed close correlation to earlier phar-
macokinetic studies [22–26] of other HSA products. The 
different uptakes of lungs and liver verified that different 
particle-diameters did not change significantly immediately 
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after intravenous injection and particles did not disaggregate. 
However, 6 hours and almost 1 day after IV application, colloid 
agents showed the proper distribution according to their particle 
size and less than 50% of injected activity excreted through the 
urinary tract.
Discussion
The present study demonstrates the preparation and inves-
tigation of doxorubicin-loaded HSA nanoparticles in different 
particle-sizes. Three samples, different by means of particle-size 
distribution and fraction-range, were considered for the ex-
periments. Non-adsorbed doxorubicin quota was checked and 
followed-up respectively, until 7 days after preparation, and verified 
that more than 95% of doxorubicin proportion was permanently 
adsorbed to human serum albumin.
Figure 7. Injected dose percentage values in liver after application.
Figure 8. Excreted activity ratio values after application.
The prepared doxorubicin-loaded particles were radiolabelled 
by 99mTc with high-degree and durable labelling efficiency as the in 
vitro radiochemical stability measurements demonstrates. Another 
aspect is the size stability: particle size was observed for 1 week. 
Each product showed a high degree of colloid size-stability: di-
ameters and polydispersities of particle fractions fluctuated within 
a relatively narrow range and changes were not unidirectional, 
nor trend-like. 
The different biological behaviours of the different-sized col-
loids were examined by scintigraphic imaging studies in healthy 
male Wistar rats. Ventrodorsal and left-lateral images were taken with 
a digital SPECT gamma camera at different times till 22 h post injec-
tion and organ uptakes were estimated by quantitative ROI analysis. 
The in vivo biodistribution data of doxorubicin-loaded radiocol-
loids had a very close correlation to earlier described results [22–26]. 
Images and calculated injected dose percentage values em-
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phasized that directly post-injection, the greatest particle-sized 
compounds were located especially in the lungs and they slowly 
disaggregated. The smaller particle fractions were relocated mainly 
in the liver and they also had slow eliminationOur investigations veri-
fied that application of different particle sized doxorubicin-loaded 
HSA nanoparticles make drug carrier systems possible to apply 
different drug targeting in potential clinical use. 
Acknowledgments
This scientific work was supported by several national 
(OTKA-68376, JEDIONKO, KMOP-1.1.1-08/1-2008-0017, 
GOP-1.1.1.-09/1-2010-0107) and international (IAEA-CRPs, EMIL 
NoE) projects. 
References
1. Mishra B, Patel BB, Tiwari S. Colloidal nanocarriers, a review on formula-
tion technology, types and applications toward targeted drug delivery. 
Nanomedicine: Nanotechnology, Biology and Medicine 2010; 6: 9–24.
2. Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N. Adriamycin-induced 
heart failure: mechanism and modulation. Mol Cell Biochem 2000; 
207: 77–86.
3. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: 
molecular advances and pharmacologic developments in antitumor 
activity and cardiotoxicity, Pharmacol Rev 2004; 56: 185–229.
4. Dreis S, Rothweiler F, Michaelis M, Cinatl J Jr, Kreuter J, Langer K. 
Preparation, characterization and maintenance of drug efficacy of 
doxorubicin-loaded human serum albumin (HSA) nanoparticles HSA. 
International Journal of Pharmaceutics 2007; 341: 207–214.
5. Cuvier C, Roblot-Treupel L, Millot JM et al. Doxorubicin-loaded nano-
spheres bypass tumor cell multidrug resistance. Biochem Pharmacol 
1992; 44: 509–517.
6. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles 
for drug delivery in cancer. Clin Cancer Res 2008; 14: 1310–1316.
7. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. 
Significant transport of doxorubicin into the brain with polysorbate 
80-coated nanoparticles. Pharm Res 1999; 16: 1564–1569.
8. Steiniger SC, Kreuter J, Khalansky AS et al. Chemotherapy of gliob-
lastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 
2004; 109: 759–767.
9. Cuvier C, Roblot-Treupel L, Millot JM et al. Doxorubicin-loaded nano-
spheres bypass tumor cell multidrug resistance. Biochem Pharmacol 
1992; 44: 509–517.
10. Yoo HS, Oh JE, Lee KH, Park TG. Biodegradable nanoparticles con-
taining doxorubicin-PLGA conjugate for sustained release. Pharm Res 
1999; 16: 1114–1118.
11. Leo E, Vandelli MA, Cameroni R, Forni F. Doxorubicin-loaded gelatin 
nanoparticles stabilized by glutaraldehyde: Involvement of the drug 
in the cross-linking process. Int J Pharm 1997; 155: 75–82.
12. Leo E, Cameroni R, Forni F. Dynamic dialysis for the drug release 
evaluation from doxorubicin-gelatin nanoparticle conjugates. Int J 
Pharm 1999; 180: 23–30.
13. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular perme-
ability and the EPR effect in macromolecular therapeutics: a review. 
J Control Rel 2000; 65: 271–284.
14. Barraud L, Merle P, Soma E et al. Increase of doxorubicin sensitivity by 
doxorubicin-loading into nanoparticles for hepatocellular carcinoma 
cells in vitro and in vivo. J Hepatol 2005; 42: 736–743.
15. Eatock M, Church N, Harris R et al. Activity of doxorubicin covalently 
bound to a novel human serum albumin microcapsule. Invest New 
Drugs 1999; 17: 111–120.
16. Weber C, Coester C, Kreuter J, Langer K. Desolvation process and 
surface characterisation of protein nanoparticles. Int J Pharm 2000; 
194: 91–102.
17. Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D. 
Optimization of the preparation process for human serum albumin 
(HSA) nanoparticles, Int J Pharm 2003; 257: 169–180.
18. Nobs L, Buchegger F, Gurny R, Allemann E. Current methods for 
attaching targeting ligands to liposomes and nanoparticles. J Pharm 
Sci 2004; 93: 1980–1992.
19. Wartlick H, Michaelis K, Balthasar S, Strebhardt K, Kreuter J, Langer K. 
Highly specific HER2-mediated cellular uptake of antibody-modified 
nanoparticles in tumour cells. J Drug Target 2004; 12: 461–471.
20. Dinauer N, Balthasar S, Weber C, Kreuter J, Langer K, von Briesen H. 
Selective targeting of antibody-conjugated nanoparticles to leukemic 
cells and primary T-lymphocytes. Biomaterials 2005; 29: 5898–5906.
21. Steinhauser I, Spänkuch B, Strebhardt K, Langer K. Trastuzumab-mo-
dified nanoparticles: optimisation of preparation and uptake in cancer 
cells. Biomaterials 2006; 28: 4975–4983.
22. Arshady R. Microspheres, microcapsules & liposomes. Citus Books, 
London 2001.
23. Mirzaei S, Rodrigues M, Hoffmann B et al. Sentinel lymph node detec-
tion with large human serum albumin colloid particles in breast cancer. 
Eur J Nucl Med Molec Imag 2003; 30: 868–873.
24. Reddy LH, Sharma RK, Chuttani K, Mishra AK, Murthy RSR. Influence of 
administration route on tumor uptake and biodistribution of etoposide 
loaded solid lipid nanoparticles in Dalton’s lymphoma tumor bearing 
mice. J Controlled Release 2005; 105: 185–198.
25. Iliuma L, Davis SS, Wilson CG, Thomas NW, Frier M, Hardy JG. Blood 
clearance and organ deposition of intravenously administered colloidal 
particles. The effects of particle size, nature and shape. International 
J Pharm 1982; 12: 135–146.
26. Whateley TL, Steele G. Particle size and surface charge studies of 
a tin colloid radiopharmaceutical for liver scintigraphy. Eur J Nucl Med 
1985; 10: 353.
27. Wagner S, Rothweiler F, Anhorn MG et al. Enhanced drug targe-
ting by attachment of an anti av integrin antibody to doxorubicin 
loaded human serum albumin nanoparticles. Biomaterials 2010; 
31: 2388–2398.
28. Configliacchi E, Razzano G, Rizzo V, Vigevani A. HPLC methods for 
the determination of bound and free doxorubicin, and of bound and 
free galactosamine, in methacrylamide polymer-drug conjugates. 
J Pharm Biomed Anal 1996; 15: 123–129.
29. Harris JR, Reiber A. Influence of saline and pH on collagen type I 
fibrillogenesis in vitro: Fibril polymorphism and colloidal gold labeling. 
Micron 2007; 38: 513–521.
30. European Pharmacopoeia 6.0, 1029–1030.
